Molecular and Cellular Biology, January 2003, p. 425-436, Vol. 23, No. 2
0270-7306/03/$08.00+0 DOI: 10.1128/MCB.23.2.425-436.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195,1 Department of Biostatistics, Epidemiology and Scientific Computing and Department of Biological and Medical Research, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia2
Received 13 June 2002/ Returned for modification 6 August 2002/ Accepted 1 October 2002
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
The molecular mechanisms by which AREs are used to fine-tune mRNA turnover are thought to involve specific RNA-binding proteins (33, 34). trans-Acting factors from different protein families that bind AREs and influence mRNA degradation have been identified. The Hu family proteins HuR and HuB have been shown to bind many different AU-rich messages and stabilize these in several different cell systems (22, 24, 25, 30, 41, 42, 44, 46, 55, 59). AUF1/heterogeneous nuclear ribonucleoprotein D binds to and destabilizes ARE mRNAs such as c-myc, granulocyte-macrophage colony-stimulating factor and others (5, 18, 43, 70). Recently, AUF1 was implicated in apoptosis as a binding factor of the Bcl2 ARE and in tumorigenesis, causing tumor development when overexpressed in mice (26, 37). Tristetraprolin, a protein from the CCCH tandem zinc finger family, appears to regulate mRNA stability of tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and interleukin-3 (7, 8, 35, 62).
The stabilizing and destabilizing activities of ARE-binding factors can in turn be regulated via a network of signal transduction, giving cells the ability to respond to extra- and intracellular signals by fine-tuning decay rates of mRNAs critical to processes such as cell growth, differentiation, and immune response. The p38 mitogen-activated protein kinase (MAP kinase) pathway has been implicated in the regulation of the mRNA half-lives of a number of AU-rich genes, including cyclooxygenase 2 (COX2), tumor necrosis factor alpha, interleukin-3, interleukin-6, interleukin-8, macrophage-inhibitory protein 1
(MIP1
), granulocyte macrophage-colony stimulating factor, vascular endothelial growth factor, and urokinase-type plasminogen activator (4, 28, 47, 48, 54, 63, 67, 70).
COX2 mRNA levels greatly increase in monocytes upon bacterial lipopolysaccharide (LPS) treatment. This induction is due to transcriptional activation and message stabilization. Inhibition of p38 with the chemical inhibitor SB203580 (SB) or by expressing dominant negative MAP kinase-activated protein kinase 2, a kinase downstream of p38, abolishes stabilization and leads to rapid degradation of COX2 mRNA (17, 39). How p38 signaling might link to ARE-binding proteins has recently been investigated for tristetraprolin. In vitro evidence shows that tristetraprolin can be directly phosphorylated by either p38 or MAP kinase-activated protein kinase 2, potentially modifying its destabilizing activity (6, 45). Alternatively, p38 may also phosphorylate ARE-stabilizing proteins that could compete with destabilizing proteins, as suggested for HuR and tristetraprolin in the case of regulating interleukin-3 decay (47).
To investigate the extent to which the p38 pathway is involved in regulating the mRNA decay of the entire spectrum of ARE-containing genes, we performed a large-scale analysis of AU-rich mRNA turnover with the AU array. This cDNA microarray with 950 ARE-containing and additional control genes was specifically constructed for this purpose. With this approach, we were able to determine the half-lives of 470 ARE mRNAs with and without p38 inhibition, allowing us to define 42 newly identified p38 MAP kinase target mRNAs.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Cell culture, treatment, and sample preparation. THP-1 cells were cultured in RPMI (Invitrogen) with 10% fetal calf serum at 37°C with 5% CO2 for 7 days prior to treatment. For treatments, cells were plated at 2.5 x 106 cells/ml in 25 ml of medium 1 h before adding drugs. LPS treatments (10 µg/ml, Escherichia coli serotype O111:B4; Sigma) were for 2 h. To measure RNA decay, actinomycin D (5 µg/ml, Sigma) alone or actinomycin D plus SB (1 µM, Calbiochem) was added to the LPS-treated cultures and harvested 30, 60, 90, 120, 180, and 240 min later for RNA and cell extract preparation. Cells were collected by sedimenting suspended cells and washing differentiating, adherent cells off the plate.
Total RNA was extracted with Trizol reagent (Invitrogen) according to the manufacturer's instructions. Whole-cell extracts were prepared after two washes with ice-cold phosphate-buffered saline with a lysis buffer containing 1% Triton X-100 as the detergent, supplemented with protease and phosphatase inhibitors (leupeptin, aprotinin, phenylmethylsulfonyl fluoride, sodium orthovanadate, and pepstatin). The LPS treatments were performed 13 times independently, giving rise to the gene induction-repression data in Table 1. The RNA decay time courses were performed three times on independently cultured THP-1 cells.
|
RNA labeling and array hybridization. For each array hybridization, RNAs from treated and untreated THP-1 cells were labeled with indocarbocyanine and indodicarbocyanine, respectively. The labeling reactions were standard cDNA syntheses incorporating labeled dUTP. The primer-annealing mixture contained 80 µg of total RNA, 2 µg of dT12-18 primer, 20 U of anti-RNase (Ambion), and 0.5 ng of each positive-control RNA in 33 µl. The four positive-control RNAs were obtained by in vitro transcription from poly(A) tail-modified bacterial gene constructs pGIBS-DAP, -PHE, -THR, and -TRP (American Type Culture Collection). The mixture was heated to 70°C for 10 min and cooled on ice.
Subsequent cDNA synthesis was at 42°C for 2 h in 50 µl with 400 U of Superscript II and 1x first-strand buffer (Invitrogen), 10 mM dithiothreitol, 0.5 mM each dATP, dCTP, and dGTP, 0.3 mM dTTP, and 3 nmol of carbocyanine-dUTP (New England Nuclear). The cDNA was purified with GFX columns following the manufacturer's instructions (Amersham Pharmacia Biotech), dried down, and resuspended in hybridization buffer containing 2x SSC, 0.1% SDS, 4 µg of poly(dA)40-60, and 4 µg of yeast tRNA. The indocarbocyanine- and indodicarbocyanine-labeled cDNAs were pooled and hybridized to the array slide under a coverglass in a Corning Microarray Technology hybridization chamber at 65°C for 16 h. Subsequently, slides were washed successively for 5 min each with 2x SSC-0.1% SDS, 2x SSC, and 0.2x SSC, spun dry, and scanned on a GenePix 4000A scanner (Axon).
Array data acquisition and normalization. Raw fluorescence data were acquired with the GenePix software (Axon). Laser settings were chosen to avoid signal saturation and achieve an overall median indocarbocyanine/indodicarbocyanine ratio of 0.8 to 1.2. The raw data were imported into the GeneSpring software version 4.2 (Silicon Genetics) for further analysis. For each gene probe, the signal intensity ratio of the treated over the untreated sample was calculated with raw fluorescent intensities, with the local background subtracted. Fluorescent intensities of the untreated samples were set to a minimum value of 300 if below that. The ratios were then normalized based on the distribution of all values with locally weighted polynomial regression (LOESS). For the decay time courses, an additional normalization was necessary because the LOESS normalization localizes the overall mean of the ratios at 1, whereas the mean of ratios naturally decreases below 1 with successive decay of the treated sample. In order to recover reality, the ratios for each array were corrected so that the mean ratio of the four positive-control probes that had been spiked into every sample in a constant amount equaled 1. To be able to compare the RNA decay observed with and without the p38 inhibitor, the average ratios from the three sets of decay time courses were finally corrected for glyceraldehyde-3-phosphate dehydrogenase based on 14 glyceraldehyde-3-phosphate dehydrogenase probes on the array.
Half-life calculations.
The natural logarithms of the average normalized ratios of treated over untreated samples (y) from three independent biological repeats with their respective standard deviations (
) were plotted against the time (x). The samples taken after 2 h of LPS treatment represent the 0-min time point from which the RNA decay measurement started. In order to exclude genes expressed at levels that are below or close to the detection limit, genes with normalized raw fluorescent intensities in the treated sample of less than the overall average background (B) plus 1 standard deviation at the 0-min time point were excluded from analysis. Lines were fit to the log-transformed data with the least-squares regression. The t1/2 was calculated as (-ln [2]/m), where m is the slope of the line fit to the data (3).
The linear regression fit was performed on from two to seven time points, and the
2 for each fit was calculated. The fit that gave the minimum
2 per degree of freedom was chosen for calculating the t1/2. Differences in t1/2 between decay with and without the p38 inhibitor were evaluated with a t-distributed statistic for distributions with unequal variances. The t statistic and the degree of freedom for the t statistic were processed to give a P value with SurfStat statistical tables online (K. Dear and R. Brennan, University of Newcastle [http://math.uc.edu/
brycw/classes/148/tables.htm]) (58). To avoid distorting the half-life calculation for rapidly decaying genes by using measurements taken at later time points, when the signal detected for this message has already reached background level, we made a second expression level cut and excluded measurements from time points when the normalized raw fluorescent intensity from the treated sample reached a level below B + 2 standard deviations.
Northern blotting.
Total RNA was fractionated on 1% agarose gels containing 0.41 M formaldehyde, capillary transferred to positively charged nylon membrane with 10x SSC, and fixed by UV cross-linking. cDNA probes (25 ng) for COX2, interleukin-1ß, interleukin-8, and glyceraldehyde-3-phosphate dehydrogenase were labeled with 50 µCi of [
-32P]dCTP by random priming. Hybridization overnight was done at 65°C in 0.5 M sodium phosphate buffer, pH 7.2, with 7% SDS, 1 mM EDTA, and 10% dextran sulfate. Blots were washed twice in 2x SSC-0.1% SDS at 65°C and exposed to X-OMAT AR film (Kodak). Signals were quantified by densitometry with ImageQuant software (Molecular Dynamics).
| RESULTS |
|---|
|
|
|---|
The highest levels of gene induction were observed for cytokines, including interleukin-1
, tumor necrosis factor alpha, interleukin-8, and many others that are part of the inflammatory response. In addition, several genes were identified that, to the best of our knowledge, have not yet been described as LPS responsive. Examples are the cleavage- and polyadenylation-specific factor 6 (also known as CF Im), a nuclear protein implicated in mRNA 3'-end processing (61), which was induced 20.7-fold. Early growth response 2 (EGR2), a zinc finger transcription factor homologous to mouse Krox-20 that is coregulated with other immediate-early genes and plays a critical role in peripheral nerve myelination (11, 31, 49, 70), was induced 14.7-fold. The regulator of G-protein signaling 16 (RGS16), a member of the RGS gene family that has been implicated in attenuation of p38 activation via G protein-linked receptors (21, 70), was induced 6.9-fold. Some novel LPS-induced genes such as the antiapoptotic genes BCL2 and BCL2-like 2 and the transcription factor nuclear factor erythroid 2-like 2 (also abbreviated Nrf2) may play a role in self-defense mechanisms that are initiated by macrophages to protect themselves from nitric oxide.
The two most highly and consistently repressed genes included growth factor-independent 1 (GFI1) and c-Myc, decreasing in expression 5- and 3.7-fold, respectively. The latter was consistently repressed in accord with its role in maintaining proliferation and preventing differentiation and apoptosis. GFI1 has recently been suggested to limit inflammatory responses by interfering with the production of cytokines such as tumor necrosis factor, interleukin-10, and interleukin-1ß (32), and hence, its repression by LPS appears logical in the context of a macrophage-initiated inflammatory response. Clearly, although our data are restricted to ARE-containing genes, the analysis of the transcriptional response of THP-1 cells to LPS can improve our understanding of macrophage defense against this bacterial toxin.
Identification of new AU-rich mRNAs stabilized by p38. The stress-activated p38 MAP kinase has previously been implicated in regulating the expression levels of a few genes via ARE-mediated mRNA turnover. To examine the effect of p38 activity on the mRNA stability of several hundred AU-rich genes in parallel, LPS-stimulated THP-1 cells were treated with actinomycin D or a combination of actinomycin D and SB for 30 to 240 min. Total RNA from treated and untreated cells was extracted, labeled, and hybridized to the AU array. Three series of independent cell treatments, RNA isolations, and array hybridizations were performed. The average half-lives, without and with SB, of all AU-rich genes that were detectable at reliable levels were calculated from the decrease in the signal ratio of treated over untreated samples.
LPS treatment highly activated p38 in THP-1 cells after 2 h of exposure, and the addition of 1 or 2 µM SB with or without actinomycin D inhibited p38 to equal levels. Importantly, the addition of actinomycin D alone did not influence the p38 activity but, when combined with SB, caused nearly complete inactivation of p38 (Fig. 1). For the following decay time courses, 1 µM SB was used because the inhibitor has been shown to be largely p38 specific at this low concentration (16, 17). Minor inhibition of the c-Jun N-terminal kinase (JNK) of 10 to 15% may occur at 2 µM SB (17).
|
|
(SCYA3), we found 42 genes which we submit as newly identified targets for p38-mediated message stabilization. Though the majority of these were inflammatory response mediators, such as the members of the small inducible cytokine subfamilies A (SCYA2, -3, -3L1, and -4) and B (GRO-1, -2, and -3, interleukin-8, and SCYB10), and the acute-phase response mediators interleukin-1
and -1ß, a variety of messages that do not appear to be directly involved in the immune response were also found to be stabilized by p38. Among these were mRNAs coding for apoptosis regulators (TNFAIP3, PMAIP6, and BCL2), transcription factors (JunB, IRF1, and SOX9), signaling kinases (MAP kinase kinase 6 and PIM1), phosphatases (PPP3CC), growth factors and receptors (FGF9 and DTR), various enzymes with metabolic, ion homeostasis, and DNA repair functions (GCH1, GAD1, CA2, PFKFB3, and UNG2), and nuclear mRNA processing factors (cleavage- and polyadenylation-specific factor 6). In summary, this variety of functionally diverse genes attests to the importance of the p38 pathway in the posttranscriptional regulation of gene expression for the class of ARE-containing genes. To confirm the array results for different genes with an alternative method, Northern blotting analyses were performed on RNA from one of the three time courses, probing for MAP kinase kinase 6, COX2, interleukin-8, interleukin-1ß, and glyceraldehyde-3-phosphate dehydrogenase (Fig. 3). Densitometry of the Northern blots for the last four was compared with the mRNA decay measured on the AU array. The results (Fig. 4) indicate that there is a tight correlation with the results obtained by densitometry of the Northern blots compared to array analysis for the three ARE-containing genes tested.
|
|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
In the present study, we used our database to make a custom cDNA array with probes representing 950 AU-rich mRNAs in order to determine the p38 dependence of mRNA stability for several hundred ARE-containing transcripts in human THP-1 monocytic cells. A role for the p38 pathway in controlling mRNA stability has so far been demonstrated for nine ARE-containing genes involved in cellular immunity, and the ARE-mediated message stabilization via p38 and the downstream MAP kinase-activated protein kinase 2 appears to be sequence specific, since the AREs of COX2 but not of c-myc or tumor necrosis factor alpha were able to confer p38-dependent stabilization on a ß-globin reporter gene in HeLa-TO cells (39). Here we have identified 42 new candidates for message stability regulation by p38 by interrogating hundreds of AU-rich mRNAs in parallel. In addition, we have presented a transcription profile of AU-rich transcript induction and repression by LPS that is based on 13 independent cell treatments and array hybridizations, and furthermore we have submitted half-lives for 425 AU-rich mRNAs that did not show stabilization by p38 in this study.
When comparing the list of ARE-containing genes that were induced by LPS with those that we found to be destabilized upon p38 inhibition, one can make two important observations that differentiate regulation at the transcriptional and posttranscriptional levels. First, many ARE-containing genes that were induced by LPS were not stabilized at the mRNA level through the p38 pathway. This observation is not surprising because LPS signaling through Toll-like receptor 4 can activate the p38 as well as the nuclear factor-
B kinase pathways via TAK1, which can subsequently turn on different sets of target genes (13, 40, 57, 66). Second, we found a number of mRNAs that were destabilized by the p38 inhibitor but not upregulated upon LPS stimulation. This finding demonstrates for the first time that the p38 pathway can control the stability of some AU-rich mRNAs that are not transcriptionally induced upon p38 activation.
A number of genes identified in this study are of particular interest in terms of the cellular response of monocytes to LPS. Regarding the signaling through the p38 pathway, it should be noted that the MAP kinase kinase 6, one of the major upstream activators of p38 (27, 53), was strongly induced by LPS (8.7-fold) and destabilized upon p38 inhibition. This finding suggests that a positive feedback loop in the p38 pathway exists that may use transcriptional induction as well as message stabilization of MAP kinase kinase 6 in order to potentiate and/or prolong the signal.
Activated macrophages produce nitric oxide as an antimicrobial and antitumor effector molecule. Okada et al. established a link between self-defense against synthesized nitric oxide and induction of Bcl2-like 1 in LPS-treated macrophages, suggesting that upregulation of this antiapoptotic factor may contribute to macrophage survival (52). Similarly, we found that Bcl2 and Bcl2-like 2 were induced by LPS, suggesting that modulation of expression of several Bcl2 family members counteracts apoptosis to promote macrophage survival. A second line of defense employed by macrophages is the upregulation of autoprotective intracellular redox buffering systems (23, 56). A novel candidate potentially involved in this process could be the nuclear factor erythroid 2-like 2 gene, which was induced by LPS 4.6-fold. This basic leucine zipper transcription factor has been implicated in the regulation of expression of detoxifying genes (10, 29) and, when deficient in mice, causes increased susceptibility to oxidative stress (9).
A gene that was stabilized through p38 but not transcriptionally induced by LPS was carbonic anhydrase 2. Carbonic anhydrases are of great physiological importance in many biological processes, including respiration, calcification, acid-base balance, bone resorption, and others (20). As catalysts of the reversible hydration of carbon dioxide, they are critical in maintaining the cellular CO2/HCO3- buffering system. Recent findings suggested that carbonic anhydrase may be important in inflammatory processes, because ambient pCO2 can modulate neutrophil activity by altering intracellular pH, thereby affecting intracellular oxidant generation and interleukin-8 secretion after LPS stimulation (14). Therefore, carbonic anhydrase 2 may also play a role in maintaining intracellular pH levels in activated macrophages, and hence, it would appear logical to stabilize the carbonic anhydrase 2 mRNA in a p38-dependent manner.
The macrophage-specific colony-stimulating factor 1 was also among the p38-stabilized messages. This regulation is noteworthy because macrophage-specific colony-stimulating factor 1 may regulate host responses to pathogens by modulating Toll-like receptor expression as treatment of macrophages with macrophage-specific colony-stimulating factor 1 downregulated Toll-like receptor 1, 2, 6, and 9 expression but not the LPS receptors Toll-like receptor 4 and 5 (64).
From an evolutionary viewpoint, we find it intriguing that the five CXC chemokines interleukin-8, GRO1, GRO2, GRO3, and SCYB10, which all showed p38-dependent message stability in our study, belong to a multigene family on chromosome 4 that most likely arose by gene duplication (51). This correlation may indicate that controlling mRNA stability could be an ancestral mechanism that developed early in the evolution of immune response regulation.
When considering the practical application of this study, it should be noted that ARE-containing genes identified as posttranscriptionally regulated by p38 are involved in different diseases. For example, interleukin-1 is expressed at abnormally high levels by glial cells in Alzheimer's disease, possibly contributing to the pathophysiology of the disease (60). Interleukin-1 was also implicated in cases of rheumatoid arthritis with severe erosive disease (15) and in early-onset periodontitis (19). For ARE mRNAs implicated in disease, the knowledge of this regulation may warrant consideration of drug intervention that may influence gene expression at the level of mRNA stability. However, the degree to which the posttranscriptional regulation of the 42 novel p38 target genes contributes to their overall level of expression and the physiological importance of this regulation will first need to be assessed on a gene-by-gene basis in the appropriate cell systems.
In conclusion, this study has provided new insights into the regulatory networks that control the response of monocytes to LPS and underlined the importance of the posttranscriptional regulation of AU-rich mRNAs through the p38 MAP kinase signaling pathway. The identification of the 42 new AU-rich transcripts that are regulated via p38 at the level of mRNA stability will further aid in understanding the molecular mechanisms by which this regulation occurs.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
2. Bakheet, T., M. Frevel, B. R. Williams, W. Greer, and K. S. Khabar. 2001. ARED: human AU-rich element-containing mRNA database reveals an unexpectedly diverse functional repertoire of encoded proteins. Nucleic Acids Res. 29:246-254.
3. Bevington, P. R., and D. K. Robinson. 1992. Method of least squares, p. 53-62. In P. R. Bevington and D. K. Robinson (ed.), Data reduction and error analysis for the physical sciences. WCB McGraw-Hill, Boston, Mass.
4. Brook, M., G. Sully, A. R. Clark, and J. Saklatvala. 2000. Regulation of tumour necrosis factor alpha mRNA stability by the mitogen-activated protein kinase p38 signalling cascade. FEBS Lett. 483:57-61.[CrossRef][Medline]
5. Buzby, J. S., G. Brewer, and D. J. Nugent. 1999. Developmental regulation of RNA transcript destabilization by A + U-rich elements is AUF1-dependent. J. Biol. Chem. 274:33973-33978.
6. Carballo, E., H. Cao, W. S. Lai, E. A. Kennington, D. Campbell, and P. J. Blackshear. 2001. Decreased sensitivity of tristetraprolin-deficient cells to p38 inhibitors suggests the involvement of tristetraprolin in the p38 signaling pathway. J. Biol. Chem. 276:42580-42587.
7. Carballo, E., W. S. Lai, and P. J. Blackshear. 1998. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science 281:1001-1005.
8. Carballo, E., W. S. Lai, and P. J. Blackshear. 2000. Evidence that tristetraprolin is a physiological regulator of granulocyte-macrophage colony-stimulating factor messenger RNA deadenylation and stability. Blood 95:1891-1899.
9. Chan, K., X. D. Han, and Y. W. Kan. 2001. An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc. Natl. Acad. Sci. USA 98:4611-4616.
10. Chan, K., and Y. W. Kan. 1999. Nrf2 is essential for protection against acute pulmonary injury in mice. Proc. Natl. Acad. Sci. USA 96:12731-12736.
11. Chavrier, P., U. Janssen-Timmen, M. G. Mattei, M. Zerial, R. Bravo, and P. Charnay. 1989. Structure, chromosome location, and expression of the mouse zinc finger gene Krox-20: multiple gene products and coregulation with the proto-oncogene c-fos. Mol. Cell. Biol. 9:787-797.
12. Chen, C. Y., and A. B. Shyu. 1995. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem. Sci. 20:465-470.[CrossRef][Medline]
13. Chow, J. C., D. W. Young, D. T. Golenbock, W. J. Christ, and F. Gusovsky. 1999. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J. Biol. Chem. 274:10689-10692.
14. Coakley, R. J., C. Taggart, C. Greene, N. G. McElvaney, and S. J. O'Neill. 2002. Ambient pCO2 modulates intracellular pH, intracellular oxidant generation, and interleukin-8 secretion in human neutrophils. J. Leukoc. Biol. 71:603-610.
15. Cox, A., N. J. Camp, C. Cannings, F. S. di Giovine, M. Dale, J. Worthington, S. John, W. E. Ollier, A. J. Silman, and G. W. Duff. 1999. Combined sib-TDT and TDT provide evidence for linkage of the interleukin-1 gene cluster to erosive rheumatoid arthritis. Hum. Mol. Genet. 8:1707-1713.
16. Cuenda, A., J. Rouse, Y. N. Doza, R. Meier, P. Cohen, T. F. Gallagher, P. R. Young, and J. C. Lee. 1995. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 364:229-233.[CrossRef][Medline]
17. Dean, J. L., M. Brook, A. R. Clark, and J. Saklatvala. 1999. p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. J. Biol. Chem. 274:264-269.
18. DeMaria, C. T., and G. Brewer. 1996. AUF1 binding affinity to A+U-rich elements correlates with rapid mRNA degradation. J. Biol. Chem. 271:12179-12184.
19. Diehl, S. R., Y. Wang, C. N. Brooks, J. A. Burmeister, J. V. Califano, S. Wang, and H. A. Schenkein. 1999. Linkage disequilibrium of interleukin-1 genetic polymorphisms with early-onset periodontitis. J. Periodontol. 70:418-430.[CrossRef][Medline]
20. Dodgson, S. J. 1991. Why are there carbonic anhydrases in the liver? Biochem. Cell Biol. 69:761-763.[Medline]
21. Druey, K. M., K. J. Blumer, V. H. Kang, and J. H. Kehrl. 1996. Inhibition of G-protein-mediated MAP kinase activation by a new mammalian gene family. Nature 379:742-746.[CrossRef][Medline]
22. Fan, X. C., and J. A. Steitz. 1998. Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAs. EMBO J. 17:3448-3460.[CrossRef][Medline]
23. Ferret, P. J., E. Soum, O. Negre, E. E. Wollman, and D. Fradelizi. 2000. Protective effect of thioredoxin upon nitric oxide-mediated cell injury in THP1 monocytic human cells. Biochem. J. 346:759-765.
24. Ford, L. P., J. Watson, J. D. Keene, and J. Wilusz. 1999. ELAV proteins stabilize deadenylated intermediates in a novel in vitro mRNA deadenylation/degradation system. Genes Dev. 13:188-201.
25. Gao, F. B., C. C. Carson, T. Levine, and J. D. Keene. 1994. Selection of a subset of mRNAs from combinatorial 3' untranslated region libraries with neuronal RNA-binding protein Hel-N1. Proc. Natl. Acad. Sci. USA 91:11207-11211.
26. Gouble, A., S. Grazide, F. Meggetto, P. Mercier, G. Delsol, and D. Morello. 2002. A new player in oncogenesis: AUF1/hnRNPD overexpression leads to tumorigenesis in transgenic mice. Cancer Res. 62:1489-1495.
27. Han, J., J. D. Lee, Y. Jiang, Z. Li, L. Feng, and R. J. Ulevitch. 1996. Characterization of the structure and function of a novel MAP kinase kinase (MKK6). J. Biol. Chem. 271:2886-2891.
28. Holtmann, H., R. Winzen, P. Holland, S. Eickemeier, E. Hoffmann, D. Wallach, N. L. Malinin, J. A. Cooper, K. Resch, and M. Kracht. 1999. Induction of interleukin-8 synthesis integrates effects on transcription and mRNA degradation from at least three different cytokine- or stress-activated signal transduction pathways. Mol. Cell. Biol. 19:6742-6753.
29. Itoh, K., T. Chiba, S. Takahashi, T. Ishii, K. Igarashi, Y. Katoh, T. Oyake, N. Hayashi, K. Satoh, I. Hatayama, M. Yamamoto, and Y. Nabeshima. 1997. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. 236:313-322.[CrossRef][Medline]
30. Jain, R. G., L. G. Andrews, K. M. McGowan, P. H. Pekala, and J. D. Keene. 1997. Ectopic expression of Hel-N1, an RNA-binding protein, increases glucose transporter (GLUT1) expression in 3T3-L1 adipocytes. Mol. Cell. Biol. 17:954-962.[Abstract]
31. Joseph, L. J., M. M. Le Beau, G. A. Jamieson, Jr., S. Acharya, T. B. Shows, J. D. Rowley, and V. P. Sukhatme. 1988. Molecular cloning, sequencing, and mapping of EGR2, a human early growth response gene encoding a protein with "zinc-binding finger" structure. Proc. Natl. Acad. Sci. USA 85:7164-7168.
32. Karsunky, H., H. Zeng, T. Schmidt, B. Zevnik, R. Kluge, K. W. Schmid, U. Duhrsen, and T. Moroy. 2002. Inflammatory reactions and severe neutropenia in mice lacking the transcriptional repressor Gfi1. Nat. Genet. 30:295-300.[CrossRef][Medline]
33. Keene, J. D. 1999. Why is Hu where? Shuttling of early-response-gene messenger RNA subsets. Proc. Natl. Acad. Sci. USA 96:5-7.
34. Keene, J. D. 2001. Ribonucleoprotein infrastructure regulating the flow of genetic information between the genome and the proteome. Proc. Natl. Acad. Sci. USA 98:7018-7024.
35. Lai, W. S., E. Carballo, J. R. Strum, E. A. Kennington, R. S. Phillips, and P. J. Blackshear. 1999. Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA. Mol. Cell. Biol. 19:4311-4323.
36. Lam, L. T., O. K. Pickeral, A. C. Peng, A. Rosenwald, E. M. Hurt, J. M. Giltnane, L. M. Averett, H. Zhao, R. E. Davis, M. Sathyamoorthy, L. M. Wahl, E. D. Harris, J. A. Mikovits, A. P. Monks, M. G. Hollingshead, E. A. Sausville, and L. M. Staudt. 2001. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol. 2:0041.1-0041.11.
37. Lapucci, A., M. Donnini, L. Papucci, E. Witort, A. Tempestini, A. Bevilacqua, A. Nicolin, G. Brewer, N. Schiavone, and S. Capaccioli. 2002. AUF1 Is a bcl-2 A + U-rich element-binding protein involved in bcl-2 mRNA destabilization during apoptosis. J. Biol. Chem. 277:16139-16146.
38. LaRue, K. E., and C. E. McCall. 1994. A labile transcriptional repressor modulates endotoxin tolerance. J. Exp. Med. 180:2269-2275.
39. Lasa, M., K. R. Mahtani, A. Finch, G. Brewer, J. Saklatvala, and A. R. Clark. 2000. Regulation of cyclooxygenase 2 mRNA stability by the mitogen-activated protein kinase p38 signaling cascade. Mol. Cell. Biol. 20:4265-4274.
40. Lee, J., L. Mira-Arbibe, and R. J. Ulevitch. 2000. TAK1 regulates multiple protein kinase cascades activated by bacterial lipopolysaccharide. J. Leukoc. Biol. 68:909-915.
41. Levine, T. D., F. Gao, P. H. King, L. G. Andrews, and J. D. Keene. 1993. Hel-N1: an autoimmune RNA-binding protein with specificity for 3' uridylate-rich untranslated regions of growth factor mRNAs. Mol. Cell. Biol. 13:3494-3504.
42. Levy, N. S., S. Chung, H. Furneaux, and A. P. Levy. 1998. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J. Biol. Chem. 273:6417-6423.
43. Loflin, P., C. Y. Chen, and A. B. Shyu. 1999. Unraveling a cytoplasmic role for hnRNP D in the in vivo mRNA destabilization directed by the AU-rich element. Genes Dev. 13:1884-1897.
44. Ma, W. J., S. Cheng, C. Campbell, A. Wright, and H. Furneaux. 1996. Cloning and characterization of HuR, a ubiquitously expressed Elav-like protein. J. Biol. Chem. 271:8144-8151.
45. Mahtani, K. R., M. Brook, J. L. Dean, G. Sully, J. Saklatvala, and A. R. Clark. 2001. Mitogen-activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor alpha mRNA stability. Mol. Cell. Biol. 21:6461-6469.
46. Maurer, F., M. Tierney, and R. L. Medcalf. 1999. An AU-rich sequence in the 3'-untranslated region of plasminogen activator inhibitor type 2 (PAI-2) mRNA promotes PAI-2 mRNA decay and provides a binding site for nuclear HuR. Nucleic Acids Res. 27:1664-1673.
47. Ming, X. F., G. Stoecklin, M. Lu, R. Looser, and C. Moroni. 2001. Parallel and independent regulation of interleukin-3 mRNA turnover by phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase. Mol. Cell. Biol. 21:5778-5789.
48. Montero, L., and Y. Nagamine. 1999. Regulation by p38 mitogen-activated protein kinase of adenylate- and uridylate-rich element-mediated urokinase-type plasminogen activator (urokinase-type plasminogen activator) messenger RNA stability and urokinase-type plasminogen activator-dependent in vitro cell invasion. Cancer Res. 59:5286-5293.
49. Nagarajan, R., J. Svaren, N. Le, T. Araki, M. Watson, and J. Milbrandt. 2001. EGR2 mutations in inherited neuropathies dominant-negatively inhibit myelin gene expression. Neuron 30:355-368.[CrossRef][Medline]
50. Nau, G. J., J. F. Richmond, A. Schlesinger, E. G. Jennings, E. S. Lander, and R. A. Young. 2002. Human macrophage activation programs induced by bacterial pathogens. Proc. Natl. Acad. Sci. USA 99:1503-1508.
51. O'Donovan, N., M. Galvin, and J. G. Morgan. 1999. Physical mapping of the CXC chemokine locus on human chromosome 4. Cytogenet. Cell Genet. 84:39-42.
52. Okada, S., H. Zhang, M. Hatano, and T. Tokuhisa. 1998. A physiologic role of Bcl-xL induced in activated macrophages. J. Immunol. 160:2590-2596.
53. Ono, K., and J. Han. 2000. The p38 signal transduction pathway: activation and function. Cell Signal. 12:1-13.[CrossRef][Medline]
54. Pages, G., E. Berra, J. Milanini, A. P. Levy, and J. Pouyssegur. 2000. Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability. J. Biol. Chem. 275:26484-26491.
55. Peng, S. S., C. Y. Chen, N. Xu, and A. B. Shyu. 1998. RNA stabilization by the AU-rich element binding protein, HuR, an ELAV protein. EMBO J. 17:3461-3470.[CrossRef][Medline]
56. Pierre-Jacques, P., S. Emmanuelle, N. Olivier, and D. Fradelizi. 2002. Auto-protective redox buffering systems in stimulated macrophages. BMC Immunol. 3:3.[CrossRef][Medline]
57. Poltorak, A., X. He, I. Smirnova, M. Y. Liu, C. V. Huffel, X. Du, D. Birdwell, E. Alejos, M. Silva, C. Galanos, M. Freudenberg, P. Ricciardi-Castagnoli, B. Layton, and B. Beutler. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085-2088.
58. Press, W. H., B. P. Flannery, S. A. Teukolsky, and W. T. Vetterling. 1986. Do two distributions have the same means or variances, p. 464-469. In W. H. Press, B. P. Flannery, S. A. Teukolsky, and W. T. Vetterling (ed.), Numerical recipes. Cambridge University Press, New York, N.Y.
59. Rodriguez-Pascual, F., M. Hausding, I. Ihrig-Biedert, H. Furneaux, A. P. Levy, U. Forstermann, and H. Kleinert. 2000. Complex contribution of the 3' untranslated region to the expressional regulation of the human inducible nitric-oxide synthase gene. Involvement of the RNA-binding protein HuR. J. Biol. Chem. 275:26040-26049.
60. Rogers, J. 2000. An interleukin-1 alpha susceptibility polymorphism in Alzheimer's disease: new fuel for the inflammation hypothesis. Neurology 55:464-465.
61. Ruegsegger, U., D. Blank, and W. Keller. 1998. Human pre-mRNA cleavage factor Im is related to spliceosomal SR proteins and can be reconstituted in vitro from recombinant subunits. Mol. Cell 1:243-253.[CrossRef][Medline]
62. Stoecklin, G., X. F. Ming, R. Looser, and C. Moroni. 2000. Somatic mRNA turnover mutants implicate tristetraprolin in the interleukin-3 mRNA degradation pathway. Mol. Cell. Biol. 20:3753-3763.
63. Stoecklin, G., P. Stoeckle, M. Lu, O. Muehlemann, and C. Moroni. 2001. Cellular mutants define a common mRNA degradation pathway targeting cytokine AU-rich elements. RNA 7:1578-1588.[Abstract]
64. Sweet, M. J., C. C. Campbell, D. P. Sester, D. Xu, R. C. McDonald, K. J. Stacey, D. A. Hume, and F. Y. Liew. 2002. Colony-stimulating factor-1 suppresses responses to CpG DNA and expression of toll-like receptor 9 but enhances responses to lipopolysaccharide in murine macrophages. J. Immunol. 168:392-399.
65. Tenenbaum, S. A., C. C Carson, P. J. Lager, and J. D. Keene. 2000. Identifying mRNA subsets in messenger ribonucleoprotein complexes by with cDNA arrays. Proc. Natl. Acad. Sci. USA 97:14085-14090.
66. Wang, C., L. Deng, M. Hong, G. R. Akkaraju, J. Inoue, and Z. J. Chen. 2001. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412:346-351.[CrossRef][Medline]
67. Wang, S. W., J. Pawlowski, S. T. Wathen, S. D. Kinney, H. S. Lichenstein, and C. L. Manthey. 1999. Cytokine mRNA decay is accelerated by an inhibitor of p38-mitogen-activated protein kinase. Inflamm. Res. 48:533-538.[CrossRef][Medline]
68. Warner, L. E., P. Mancias, I. J. Butler, C. M. McDonald, L. Keppen, K. G. Koob, and J. R. Lupski. 1998. Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat. Genet. 18:382-384.[CrossRef][Medline]
69. Winzen, R., M. Kracht, B. Ritter, A. Wilhelm, C. Y. Chen, A. B. Shyu, M. Muller, M. Gaestel, K. Resch, and H. Holtmann. 1999. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J. 18:4969-4980.[CrossRef][Medline]
70. Zhang, W., B. J. Wagner, K. Ehrenman, A. W. Schaefer, C. T. DeMaria, D. Crater, K. DeHaven, L. Long, and G. Brewer. 1993. Purification, characterization, and cDNA cloning of an AU-rich element RNA-binding protein, AUF1. Mol. Cell. Biol. 13:7652-7665.
71. Zhang, Y., S. Y. Neo, J. Han, L. P. Yaw, and S. C. Lin. 1999. RGS16 attenuates g
q-dependent p38 mitogen-activated protein kinase activation by platelet-activating factor. J. Biol. Chem. 274:2851-2857.
This article has been cited by other articles: